LeBel Carl 4

4 · Frequency Therapeutics, Inc. · Filed Aug 19, 2022

Form 4

Period: 2022-08-17

Chief Development Officer

Transactions

Disposition to Issuer
Stock Option
2022-08-17−75,000→ 0 total
Exercise: $35.85Exp: 2031-01-14→ Common Stock (75,000 underlying)
Award
Stock Option
2022-08-17+178,937→ 178,937 total
Exercise: $2.14Exp: 2029-10-01→ Common Stock (178,937 underlying)
Disposition to Issuer
Stock Option
2022-08-17−178,937→ 0 total
Exercise: $14.00Exp: 2029-10-01→ Common Stock (178,937 underlying)
Award
Stock Option
2022-08-17+75,000→ 75,000 total
Exercise: $2.14Exp: 2031-01-14→ Common Stock (75,000 underlying)
Award
Stock Option
2022-08-17+57,500→ 57,500 total
Exercise: $2.14Exp: 2030-02-11→ Common Stock (57,500 underlying)
Disposition to Issuer
Stock Option
2022-08-17−57,500→ 0 total
Exercise: $25.05Exp: 2030-02-11→ Common Stock (57,500 underlying)

Footnotes (4)

[F1]The option vests and becomes exercisable in equal monthly installments over a four year period commencing on November 2, 2019, and will be fully vested and exercisable on October 2, 2023.
[F2]The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.
[F3]The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2021, and will be fully vested and exercisable on January 1, 2025.
[F4]The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2020, and will be fully vested and exercisable on January 1, 2024.

Documents

1 file